ArticleWorld journal of clinical cases2019
HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer.
Article in World journal of clinical cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.Cancer medicine · 2023Trial
- Evolving precision: Updates in targeted therapy for cholangiocarcinoma.Hepatology (Baltimore, Md.) · 2026Review
- UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA).ESMO gastrointestinal oncology · 2026Article
- HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies.International journal of molecular sciences · 2026Review
- Multi-institutional assessment of HER2 immunohistochemistry in gastric and esophagogastric junction cancer.iScience · 2026Article
- Bispecific Antibodies and Antibody-Drug Conjugates in Advanced Gastric Adenocarcinoma.Cancers · 2026Review
- HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry.JCO precision oncology · 2026Article
- Emerging Concepts in Immuno-Oncology: Insights from Natural Language Processing-Driven Co-Occurrence Analysis.ACS omega · 2025Review
- Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2Scientific reports · 2025Article
- Expression of HER2 in urothelial carcinoma and its significance.Current urology · 2025Article
- Deep learning-based prediction of HER2 status and trastuzumab treatment efficacy of gastric adenocarcinoma based on morphological features.Journal of translational medicine · 2025Article
- Spatial and Temporal Tumor Heterogeneity in Gastric Cancer: Discordance of Predictive Biomarkers.Journal of gastric cancer · 2025Review
- HER2-targeted therapies beyond breast cancer - an update.Nature reviews. Clinical oncology · 2024Review
- Current and Future Biomarkers in Esophagogastric Adenocarcinoma.Journal of gastrointestinal cancer · 2024Review
- Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma.Pathology international · 2024Review
- Significant effect of posterior line treatment of HER2 positive advanced gastric cancer: A case report.Heliyon · 2024Article
- The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells.World journal of oncology · 2024Article
- Deep learning model based on multi-lesion and time series CT images for predicting the benefits from anti-HER2 targeted therapy in stage IV gastric cancer.Insights into imaging · 2024Article
- Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond.Journal of gastric cancer · 2024Review
- Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target.Cancers · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical significance of intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity is unclear for HER2-positive gastric cancer, although it has been reported to be a significant prognosticator for HER2-positive breast cancer, which has received trastuzumab-based chemotherapy.
aimTo clarify the clinical significance of intratumoral HER2 heterogeneity for HER2-positive gastric cancer, which has received trastuzumab-based chemotherapy.
methodsPatients with HER2-positive unresectable or metastatic gastric cancer who received trastuzumab-based chemotherapy as a first line treatment were included. The patients were classified into two groups according to their intratumoral HER2 heterogeneity status examined by immunohistochemistry (IHC) on endoscopic biopsy specimens before treatment, and their clinical response to chemotherapy and survival were compared.
resultsA total of 88 patients were included in this study, and HER2 heterogeneity was observed in 23 (26%) patients (Hetero group). The overall response rate was significantly better in patients without HER2 heterogeneity (Homo group) (Homo
conclusionIHC of HER2 heterogeneity is the pivotal predictor for trastuzumab-based chemotherapy. Thus, HER2 heterogeneity should be considered during the assessment of HER2 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.